Department of Public Health, Federal University of Parana, Rua General Carneiro, 181, Curitiba, PR, 80600900, Brazil.
Mycopathologia. 2013 Jun;175(5-6):477-88. doi: 10.1007/s11046-013-9648-x. Epub 2013 May 2.
Chromoblastomycosis (CBM) is an implantation mycosis mainly occurring in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM require long-term therapy with systemic antifungals flanked by various physical treatment regimens. As in other neglected endemic mycoses, comparative clinical trials have not been performed for this disease; nowadays, therapy is mainly based on a few open trials and on expert opinions. Itraconazole, either as monotherapy or associated with other drugs, or with physical methods, is widely used. Recently, photodynamic therapy has been employed successfully in combination with antifungals in patients presenting with CBM. In the present paper, the most used therapeutic options against CBM are reviewed as well as the several factors that may have impact on the patient's outcome.
着色芽生菌病（CBM）是一种主要发生在全球热带和亚热带地区的植入性真菌病。如果不在早期阶段诊断，CBM 患者需要长期接受全身性抗真菌药物治疗，并辅以各种物理治疗方案。与其他被忽视的地方性真菌病一样，针对这种疾病尚未进行对照临床试验；如今，治疗主要基于少数开放试验和专家意见。伊曲康唑，无论是单独使用还是与其他药物联合使用，或与物理方法联合使用，都被广泛应用。最近，光动力疗法已成功地与抗真菌药物联合应用于 CBM 患者。本文综述了治疗 CBM 的最常用方法，以及可能影响患者预后的多种因素。
